BioSpace News Archive

ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the closing of its previously announced registered direct offering with certain institutional and accredited investors of 348,000 shares of ARCA’s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 3

Garsite, a leading manufacturer of aviation refueling and specialty pumping equipment, announces the launch of its line of disinfecting equipment.

Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors.

Initiation of intravenous Factor VIII treatment in early childhood improves joint outcomes in young adulthood

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, announced updated results from the Phase 1b portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:

ViewRay, Inc. announced grants of stock options and restricted stock units to Zach Stassen, Chief Financial Officer for the company.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the pricing of an underwritten public offering of 3,030,303 shares of its common stock at a price to the public of $33.00 per share.

Covalon Technologies Ltd., an advanced medical technologies company, announced that the Company has been granted key antimicrobial patents by the United States Patent and Trademark Office, the Canadian Intellectual Property Office, and the European Patent Office.